 |
市場調查報告書
商品編碼
1672738
遺傳性血管性水腫市場按類型、藥物類別、給藥途徑、分銷管道和地區分類Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
2025 年全球遺傳性血管性水腫市場規模估計為 31.3 億美元，預計到 2032 年將達到 59.6 億美元，2025 年至 2032 年的複合年成長率為 9.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 31.3億美元 |
| 效能資料 | 從 2020 年到 2024 年 | 預測期 | 2025 至 2032 年 |
| 預測期：2025-2032年複合年成長率： | 9.60％ | 2032 年價值預測 | 59.6億美元 |
遺傳性血管性水腫是一種罕見的遺傳性疾病，其特徵是復發性嚴重的皮下或黏膜下水腫。症狀包括手、腳、四肢、臉部、腸道和呼吸道腫脹。這些發作是由於 C1 抑制劑水平或功能下降引起的，C1 抑制劑是一種控制補體和纖溶系統某些部分的血清蛋白。患有遺傳性血管性水腫的患者平均每四周至少會出現一次水腫，通常需要醫療干預來控制症狀。該疾病在全球範圍內的流行率不斷上升以及對可用治療方案的認知不斷提高，可能會推動遺傳性血管性水腫市場的成長。
市場動態
對替代治療方法的研究不斷增加、全球 HAE 盛行率不斷上升、 FDA認證核可藥的可用性以及對該疾病的認知不斷提高，可能會推動遺傳性血管性水腫市場的成長。然而，HAE 治療的高成本和新興國家的低認知度可能會阻礙市場的成長。皮下C1-INH產品和口服療法的開發將為市場相關人員提供新的機會。
本研究的主要特點
本報告對全球遺傳性血管性水腫市場進行了詳細分析，並給出了預測期（2025-2032）的市場規模和年複合成長率（CAGR%），假設 2024 年為基準年。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球遺傳性血管性水腫市場的關鍵參與者根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行分析。
主要公司包括 CSL Behring、賽諾菲、武田藥品工業株式會社、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnologies, Inc.、KalVista Pharmaceuticals 和 CENTOGENE NV。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
全球遺傳性血管性水腫市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球遺傳性血管性水腫市場的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- 遺傳性血管性水腫市場（按類型）
- 遺傳性血管性水腫市場（依藥物類別）
- 遺傳性血管性水腫市場（依給藥途徑）
- 遺傳性血管性水腫市場，依分銷管道分類
- 遺傳性血管性水腫市場（按地區）
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管情景
- 產品發布/核准
- PEST分析
- PORTER 分析
- 併購情景
- 流行病學
- 管道分析
4. 遺傳性血管性水腫市場，依類型，2020-2032 年（十億美元）
- 2025 年及 2032 年市場佔有率分析（%）
- 與前一年同期比較成長分析
- 細分趨勢
- 遺傳性血管性水腫 I 型
- 市場規模及預測，與前一年同期比較（十億美元）
- 遺傳性血管性水腫 II 型
- 市場規模及預測，與前一年同期比較（十億美元）
5. 遺傳性血管性水腫市場，依藥物類別，2020-2032 年（十億美元）
- 2025 年及 2032 年市場佔有率分析（%）
- 與前一年同期比較成長分析
- 細分趨勢
- C1 酯酶抑制劑
- 市場規模及預測，與前一年同期比較（十億美元）
- 激肽釋放酶抑制劑
- 市場規模及預測，與前一年同期比較（十億美元）
- 緩激肽受體
- 市場規模及預測，與前一年同期比較（十億美元）
- 雄激素減弱
- 市場規模及預測，與前一年同期比較（十億美元）
- 其他
- 市場規模及預測，與前一年同期比較（十億美元）
6. 遺傳性血管性水腫市場，依給藥途徑，2020-2032 年（十億美元）
- 2025 年及 2032 年市場佔有率分析（%）
- 與前一年同期比較成長分析
- 細分趨勢
- 皮下
- 市場規模及預測，與前一年同期比較（十億美元）
- 靜脈
- 市場規模及預測，與前一年同期比較（十億美元）
- 口服
- 市場規模及預測，與前一年同期比較（十億美元）
7. 遺傳性血管性水腫市場，按分銷管道，2020-2032 年（十億美元）
- 2025 年及 2032 年市場佔有率分析（%）
- 與前一年同期比較成長分析
- 細分趨勢
- 醫院藥房
- 市場規模及預測，與前一年同期比較（十億美元）
- 零售藥局
- 市場規模及預測，與前一年同期比較（十億美元）
- 網路藥局
- 市場規模及預測，與前一年同期比較（十億美元）
8. 遺傳性血管性水腫市場，按地區，2020-2032 年（十億美元）
- 2025 年、2028 年、2032 年市場佔有率(%) 分析（單位：十億美元）
- 市場與前一年同期比較分析（%），（十億美元）
- 區域趨勢
- 北美洲
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國市場規模及預測（十億美元）
- 拉丁美洲
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國市場規模及預測（十億美元）
- 歐洲
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國市場規模及預測（十億美元）
- 亞太地區
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國市場規模及預測（十億美元）
- 中東
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國市場規模及預測（十億美元）
- 非洲
- 市場規模及預測（按類型分類）（十億美元）
- 市場規模及預測（按藥品類別分類）（十億美元）
- 按給藥途徑分類的市場規模和預測（十億美元）
- 按分銷管道分類的市場規模和預測（十億美元）
- 各國家/地區市場規模及預測（十億美元）
第9章 競爭格局
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group NV
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE NV
第 10 章分析師建議
第 11 章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Global Hereditary Angioedema Market is estimated to be valued at USD 3.13 Bn in 2025 and is expected to reach USD 5.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.13 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.60% | 2032 Value Projection: | USD 5.96 Bn |
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.
Market Dynamics
Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.
Key features of the study
This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2032)
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
- Subcutaneous
- Intravenous
- Oral
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2019 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Hereditary Angioedema Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Hereditary Angioedema Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Hereditary Angioedema Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Hereditary Angioedema Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Hereditary Angioedema Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
遺傳性血管性水腫治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、配銷通路、應用、地區和競爭細分，2020-2030 年預測
遺傳性血管性水腫治療市場規模、佔有率、成長分析、按治療方法、按給藥途徑、按分銷管道、按最終用途、按地區 - 行業預測，2025-2032 年
遺傳性血管水腫治療藥物市場：依藥物類別、治療類型、給藥途徑分類 - 2025-2030 年全球預測
遺傳性血管水腫 (HAE) 治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032
遺傳性血管水腫治療藥物市場規模、佔有率和趨勢分析報告：2023-2030 年按治療、給藥途徑、最終用途、地區和細分市場分類的趨勢